Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

190.30 -0.21 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
BeiGene: Q4 Earnings Insights
BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia
The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for... 
Via Benzinga
CStone's Commercialization Capacity Put to Test With Latest Drug Approval
Key takeaways: 
Via Benzinga
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
From BeiGene, Ltd.
Via Business Wire
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
From BeiGene
Via Business Wire
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept... 
Via Benzinga
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own... 
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric... 
Via Benzinga
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From BeiGene
Via Business Wire
Death Cross Looms Over BeiGene Investors
If history is any guide, there may be trouble ahead for shares of BeiGene (NASDAQ:BGNE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis... 
Via Talk Markets
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders. 
Via InvestorPlace
Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B
BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and... 
Via Benzinga
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
From BeiGene, Ltd.
Via Business Wire
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.